Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jonathan W. Goldman, MD"'
Autor:
Clayton P. Smith, MD, Michael Xiang, MD, PhD, Stephanie M. Yoon, MD, Alan Lee, MD, Dan Ruan, PhD, Jonathan W. Goldman, MD, Amy L. Cummings, MD, Aaron Lisberg, MD, Edward B. Garon, MD, MS, Drew Moghanaki, MD, MPH
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100468- (2023)
Introduction: Osimertinib is an effective treatment for metastatic NSCLC. Occasionally, thoracic radiation therapy (TRT) is delivered to patients receiving osimertinib to treat residual or progressing pulmonary tumors. Anecdotal reports suggest that
Externí odkaz:
https://doaj.org/article/b2b61572fb9f435fa78b46c90498509e
Autor:
David J. Benjamin, MD, Shuai Chen, PhD, Joanna B. Eldredge, MD, Shiruyeh Schokrpur, MD, Debory Li, Zhikuan Quan, MS, Jason W. Chan, MD, Amy L. Cummings, MD, Megan E. Daly, MD, Jonathan W. Goldman, MD, Matthew A. Gubens, MD, Jeremy P. Harris, MD, Mark W. Onaitis, MD, Viola W. Zhu, MD, PhD, Sandip P. Patel, MD, Karen Kelly, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 12, Pp 100427- (2022)
Introduction: There is a paucity of data on immune checkpoint inhibitors (ICIs) plus doublet chemotherapy (C) in patients with advanced lung cancer whose tumor harbors an actionable mutation. We sought to provide insight into the role of this combina
Externí odkaz:
https://doaj.org/article/3801fd9322224ff8af798db8607d43fe
Autor:
Yuanbin Chen, MD, PhD, Luis Paz-Ares, MD, PhD, Niels Reinmuth, MD, PhD, Marina Chiara Garassino, MD, Galina Statsenko, MD, Maximilian J. Hochmair, MD, Mustafa Özgüroğlu, MD, PhD, Francesco Verderame, MD, Libor Havel, MD, György Losonczy, MD, PhD, Nikolay V. Conev, MD, PhD, Katsuyuki Hotta, MD, PhD, MPH, Jun Ho Ji, MD, PhD, Stuart Spencer, MSc, Tapashi Dalvi, PhD, MPH, Haiyi Jiang, MD, Jonathan W. Goldman, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100330- (2022)
Introduction: In the phase 3 study involving the use of durvalumab with or without tremelimumab in combination with platinum-based chemotherapy in untreated extensive-stage SCLC (CASPIAN study), first-line durvalumab plus platinum-etoposide (EP) sign
Externí odkaz:
https://doaj.org/article/1c079ba625de443f80bdb5548364cf07
Autor:
D. Ross Camidge, MD, PhD, Fabrice Barlesi, MD, PhD, Jonathan W. Goldman, MD, Daniel Morgensztern, MD, Rebecca Heist, MD, MPH, Everett Vokes, MD, Eric Angevin, MD, PhD, David S. Hong, MD, Igor I. Rybkin, MD, Minal Barve, MD, Todd M. Bauer, MD, Angelo Delmonte, MD, Martin Dunbar, DrPH, Monica Motwani, PhD, Apurvasena Parikh, PhD, Elysa Noon, PhD, Jun Wu, MD, Vincent Blot, PhD, Karen Kelly, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100262- (2022)
Introduction: Telisotuzumab vedotin (Teliso-V) is an anti-c-Met–directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC. Its potential activity combined with programmed cell death protein-1 inhibitors has not
Externí odkaz:
https://doaj.org/article/5db379369d064b09bb9b7152b523f622